Did Omeros beat or miss consensus estimates last quarter?

What factors drove the changes in Omeros's revenue and profit?

What does Omeros do and what are its main business segments?

What is the market's earnings forecast for Omeros next quarter?

What is Omeros's latest dividend and current dividend yield?

What is Omeros's gross profit margin?

What were the key takeaways from Omeros's earnings call?

What guidance did Omeros's management provide for the next earnings period?

- **$2.1B Strategic Deal**: Novo Nordisk collaboration provides $240M upfront and $100M near-term milestones.
- **Financial Turnaround**: Reduced debt by 80% to $17.1M; 2027 cash flow positive.
- **YARTEMLEA Launch**: FDA approval expected Q4; NTAP coverage secured.
- **Pipeline Expansion**: MASP-2 antibody (Phase 2), PDE7, and T-CAT programs advancing.

**【CEO Summary Section】**
- Announced a strategic collaboration with Novo Nordisk valued at up to $2.1 billion, including $240 million upfront payment and $100 million near-term milestones.
- Repositioned balance sheet with $36.1 million cash on hand and secured $20 million in debt repayment through the Novo transaction.
- YARTEMLEA (narsoplimab) FDA approval expected in Q4 2025 with commercial launch preparations finalized across 15+ transplant centers.
- Expanded pipeline includes MASP-2 antibody (OMS1029), PDE7, and T-CAT platforms, with Phase 2 studies initiated.

**【CFO Financial Commentary】**
- Q3 2025 net loss of $30.9 million ($0.47/share) vs. Q2 loss of $25.4 million ($0.43/share).
- Adjusted cash burn of $22 million, with $20 million raised through registered direct offering.
- Projected 2027 cash flow positivity post-Novo transaction.
- Repaid $67.1 million term loan and $17.1 million convertible notes, reducing debt by 80%.

**【Q&A Highlights】**
- FDA approval decision for YARTEMLEA expected in Q4; NTAP coverage discussions underway.
- Formulary access agreements secured with 75% of high-volume transplant centers.
- Historical control analysis validates YARTEMLEA's 30% survival benefit vs. standard care.
- 2026 operating expenses projected to increase 15% for launch-related costs.
- Novo collaboration excludes Omeros' MASP-2 small molecule programs, maintaining pipeline control.

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

OMER

OMER fundamentals

You can ask Aime